[Serum sickness induced by rituximab infusion; report of two cases with hematological malignancies].
Rinsho Ketsueki
; 50(4): 304-8, 2009 Apr.
Article
en Ja
| MEDLINE
| ID: mdl-19404025
ABSTRACT
We report 2 cases of serum sickness after rituximab infusion. Case 1 is a patient with Waldenström's macroglobulinemia, and case 2 is a patient with marginal-zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT) type and Sjögren's syndrome. Both patients had polyclonal hypergammaglobulinemia, were treated with rituximab monotherapy, developed serum sickness between 9 and 17 days after the first rituximab infusion, developed fever and arthralgia, and improved soon after corticosteroid treatment. Serum sickness after rituximab treatment for hematological malignancies is very rare as far as we know. We identified three risk factors of serum sickness after rituximab infusion from previous reports and our cases; administration of rituximab alone, the existence of Sjögren's syndrome, and polyclonal hypergammaglobulinemia.
Buscar en Google
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Enfermedad del Suero
/
Macroglobulinemia de Waldenström
/
Linfoma de Células B de la Zona Marginal
/
Anticuerpos Monoclonales
/
Antineoplásicos
Tipo de estudio:
Etiology_studies
/
Prognostic_studies
/
Risk_factors_studies
Límite:
Aged
/
Female
/
Humans
/
Middle aged
Idioma:
Ja
Revista:
Rinsho Ketsueki
Año:
2009
Tipo del documento:
Article